Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Equity Average: 2020-2025

Historic Equity Average for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $273.6 million.

  • Mirum Pharmaceuticals' Equity Average rose 18.70% to $273.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.6 million, marking a year-over-year increase of 18.70%. This contributed to the annual value of $237.2 million for FY2024, which is 21.40% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Equity Average stood at $273.6 million for Q3 2025, which was up 12.04% from $244.2 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Equity Average peaked at $273.6 million during Q3 2025, and registered a low of $76.1 million during Q3 2021.
  • Over the past 3 years, Mirum Pharmaceuticals' median Equity Average value was $230.5 million (recorded in 2024), while the average stood at $214.9 million.
  • In the last 5 years, Mirum Pharmaceuticals' Equity Average slumped by 40.68% in 2021 and then spiked by 110.95% in 2024.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Equity Average stood at $88.3 million in 2021, then surged by 76.29% to $155.7 million in 2022, then soared by 66.30% to $258.9 million in 2023, then decreased by 11.61% to $228.8 million in 2024, then rose by 18.70% to $273.6 million in 2025.
  • Its Equity Average stands at $273.6 million for Q3 2025, versus $244.2 million for Q2 2025 and $229.4 million for Q1 2025.